Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin

被引:55
作者
Agnello, D
Bertini, R
Sacco, S
Meazza, C
Villa, P
Ghezzi, P
机构
[1] Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy
[2] Dompe SPA Res Ctr, Dept Pharmacol, I-67100 Laquila, Italy
[3] CNR, Cellular & Mol Pharmacol Ctr, I-20129 Milan, Italy
来源
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 1998年 / 275卷 / 05期
关键词
inflammation; cytokines; corticotropin-releasing factor; lipopolysaccharide; hypothalamus-pituitary-adrenal axis; interleukin-1; interleukin-6; Kupffer cells;
D O I
10.1152/ajpendo.1998.275.5.E757
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Urocortin (UCN) is a neuropeptide homologous with corticotropin-releasing factor (CRF), which has anti-inflammatory activities not all mediated by corticosteroids. In mice, UCN (1 mu g/mouse sc) significantly reduced lipopolysaccharide (LPS)-induced serum tumor necrosis factor (TNF) and interleukin (IL)-1 beta levels in vivo but did not affect serum IL-6. These effects were paralleled by a rise in corticosterone (CS) levels. Blockade of the CS increase by cyanoketone did not prevent TNF inhibition by UCN, suggesting the neuropeptide has anti-inflammatory mechanisms independent of the hypothalamus-pituitary-adrenal axis. In fact UCN had a direct inhibitory effect on LPS-induced TNF in rat Kupffer cells at concentrations between 10(-10) and 10(-16) M, and this effect was related to increased cAMP levels. However, the in vivo inhibition of LPS-induced IL-1 beta by UCN was reversed by cyanoketone, indicating that the increase of endogenous glucocorticoids might be more important in IL-1 beta inhibition than in TNF inhibition by UCN.
引用
收藏
页码:E757 / E762
页数:6
相关论文
共 34 条
  • [1] AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345
  • [2] ADRENALECTOMY SENSITIZES MICE TO THE LETHAL EFFECTS OF INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR
    BERTINI, R
    BIANCHI, M
    GHEZZI, P
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (05) : 1708 - 1712
  • [3] Immunosuppressive phenotype of corticotropin-releasing factor transgenic mice is reversed by adrenalectomy
    Boehme, SA
    Gaur, A
    Crowe, PD
    Liu, XJ
    Tamraz, S
    Wong, T
    Pahuja, A
    Ling, N
    Vale, W
    DeSouza, EB
    Conlon, PJ
    [J]. CELLULAR IMMUNOLOGY, 1997, 176 (02) : 103 - 112
  • [4] CHENSUE SW, 1991, AM J PATHOL, V138, P395
  • [5] SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS AND IMMUNE-MEDIATED INFLAMMATION
    CHROUSOS, GP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20) : 1351 - 1362
  • [6] Modulation of the inflammatory response by corticotropin-releasing factor
    Correa, SG
    Riera, CM
    Spiess, J
    Bianco, ID
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 319 (01) : 85 - 90
  • [7] CORTICOTROPIN-RELEASING FACTOR BINDING TO PERIPHERAL TISSUE AND ACTIVATION OF THE ADENYLATE CYCLASE-ADENOSINE 3',5'-MONOPHOSPHATE SYSTEM
    DAVE, JR
    EIDEN, LE
    ESKAY, RL
    [J]. ENDOCRINOLOGY, 1985, 116 (06) : 2152 - 2159
  • [8] RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS
    ELLIOTT, MJ
    MAINI, RN
    FELDMANN, M
    KALDEN, JR
    ANTONI, C
    SMOLEN, JS
    LEEB, B
    BREEDVELD, FC
    MACFARLANE, JD
    BIJL, H
    WOODY, JN
    [J]. LANCET, 1994, 344 (8930) : 1105 - 1110
  • [9] ENDRES S, 1991, IMMUNOLOGY, V72, P56
  • [10] GLUCOCORTICOIDS AS CYTOKINE INHIBITORS - ROLE IN NEUROENDOCRINE CONTROL AND THERAPY OF INFLAMMATORY DISEASES
    FANTUZZI, G
    GHEZZI, P
    [J]. MEDIATORS OF INFLAMMATION, 1993, 2 (04) : 263 - 270